Related Experiment Videos
[Clinical experience with cefodizime on pediatric infections]
Insights
Cefodizime (CDZM), a new injectable antibiotic, showed excellent or good clinical efficacy in pediatric infections. This antibiotic demonstrated effectiveness with no severe adverse reactions observed in the study.
Area of Science:
- Pharmacology
- Infectious Diseases
- Pediatrics
Context:
- Cefodizime (CDZM) is a novel injectable cephem antibiotic.
- Pediatric infections pose a significant health challenge.
- Evaluating new antibiotic treatments is crucial for combating resistant pathogens.
Purpose:
- To assess the clinical efficacy and safety of Cefodizime (CDZM) in treating pediatric infections.
- To monitor the impact of Cefodizime on common bacterial pathogens in pediatric patients.
- To document any adverse reactions or laboratory abnormalities associated with Cefodizime administration.
Summary:
- Cefodizime was administered intravenously to 13 pediatric patients at 20 mg/kg thrice daily.
- Clinical efficacy was rated excellent in 4/10 cases and good in 6/10 cases, excluding Mycoplasma pneumonia.
- Pathogen elimination was observed for Streptococcus pyogenes, Klebsiella pneumoniae, and Haemophilus influenzae; no severe adverse reactions were reported.
Impact:
- Cefodizime demonstrates promising efficacy and a favorable safety profile for treating various pediatric bacterial infections.
- The study supports Cefodizime as a potential therapeutic option in pediatric infectious disease management.
- Further research may explore Cefodizime's role in broader pediatric infectious disease contexts.
Abstract:
Cefodizime (THR-221, CDZM), a newly developed injectable cephem antibiotic, was injected intravenously to 13 cases of pediatric infections. Patients received the drug at a dose level of approximately 20 mg/kg x 3 times daily. The results obtained are summarized as follows. 1. Clinical efficacy was excellent in 4 patients, good in 6 and poor in 0 for 10 cases (2 phlegmon, 1 periproctal abscess, 5 pneumonia and 2 bronchitis) except 3 Mycoplasma pneumonia. 2. Three strains of pathogens were followed for their changes (Streptococcus pyogenes in 1 phlegmon, Klebsiella pneumoniae in periproctal abscess and Haemophilus influenzae in 1 bronchitis) and they were found to have been eliminated. 3. No adverse reactions occurred. Abnormal changes in laboratory test data found were 2 cases of eosinophilia, 1 cash each of increased GOT and GPT, and thrombocytosis, but none of them was severe.